Spruce Biosciences, Inc. SPRB
45.04 USD +1.72 (+3.98%)
As ofNov 16, 2026, 9:30 AM EST
45.04 Day range 45.04
38.06 52-week range 127.90
- YTD
- -48.30%
- 1 year
- -57.65%
News
benzinga.com Spruce Biosciences Q3 EPS $(8.51) Up From $(14.58) YoY Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(8.51) per share. This is a 41.63 percent increase over losses of $(14.58) per share from the same period last year.
businesswire.com Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…benzinga.com Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences, Plans Spin-Off To Stockholders Transaction Expected to Create Two Independent, Publicly Traded Companies with Distinct Strategic Priorities, Separate Capital Structures and Dedicated TeamsUp to $50 Million Committed to Adrenyx…
businesswire.com Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
